Publicação científica trimestral do CREMERJ - número 2 - 2022

62 Fibrilação Atrial – diagnóstico, fisiopatologia e terapêutica Eduardo B. Saad e Charles Slater Med. Ciên. e Arte , Rio de Janeiro, v.1, n.2, p.49-62, abr-jun 2022 9. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994. doi:10.1001/ jama.1994.03510350050036 10. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham heart study. Circulation. 2003. doi:10.1161/01. CIR.0000072767.89944.6E 11. Gami AS, Hodge DO, Herges RM, et al. Obstructive Sleep Apnea, Obesity, and the Risk of Incident Atrial Fibrillation. J Am Coll Cardiol. 2007. doi:10.1016/j.jacc.2006.08.060 12. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Med. 2005. doi:10.1016/j.amjmed.2005.01.031 13. Conen D, Tedrow UB, Cook NR, Moorthy M V, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA. 2008. doi:10.1001/jama.2008.755 14. Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010. doi:10.1001/jama.2010.1690 15. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012. doi:10.1038/ng.2261.Meta-analysis 16. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991. doi:10.1161/01.STR.22.8.983 17. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003. doi:10.1016/j. accreview.2003.09.035 18. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867. doi:10.7326/0003-4819- 146-12-200706190-00007 19. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009. doi:10.1056/NEJMoa0905561 20. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011. doi:10.1056/NEJMoa1009638 21. Granger CB, Alexander JH, McMurray JJ V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011. doi:10.1056/NEJMoa1411087 22. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013. doi:10.1056/NEJMoa1310907 23. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. EP Eur. 2018;20(1):e1-e160. doi:10.1093/ europace/eux274 24. Zhang LT, Gay M. Characterizing left atrial appendage functions in sinus rhythm and atrial fibrillation using computational models. J Biomech. 2008;41(11):2515-2523. doi:10.1016/j.jbiomech.2008.05.012 25. Reddy VY, Sievert H, Halperin J, et al. Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation. JAMA. 2014;312(19):1988-1998. doi:10.1001/jama.2014.15192 26. Osmancik P, Herman D, Neuzil P, et al. Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulants in High-Risk Patients with Atrial Fibrillation. J Am Coll Cardiol 2020; 75: 3122-3135 doi 10.1016/j. jacc.2020.04.067